Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of epirubicin, cisplatin and capecitabine in carcinomas of unknown primary with prospective validation of molecular classifiers
2008-000657-35Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Aug 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of epirubicin, cisplatin and capecitabine in carcinoma of unknown primary site (CUP), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Diagnostic accuracy of molecular classifiers. Started Aug 2008; status: completed.
02
Drugs
epirubicincisplatincapecitabine
03
Conditions
carcinoma of unknown primary site (CUP)
Beyond the preview
Go deeper on 2008-000657-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000657-35.